Footer - SciNeuro Pharmaceuticals

SNP614

Leucine-rich repeat kinase 2(LRRK2) is a multifunctional protein with GTPase & kinase activities. LRRK2 gene mutations are associated with increased activities of LRRK2 protein, conferring elevated risk for Parkinson’s disease (PD). SNP614 is a chemically modified antisense oligonucleotide (ASO) efficiently downregulates LRRK2 mRNA thereby lowering its levels and activities linked to PD development and progression. ASO treatment enables a disease-modifying therapy and is superior to current standard of care (SoC) symptomatic approaches.

SNP210

Cytoplasmic TDP-43 (transactive response DNA binding protein of 43 kDa) forms toxic aggregates featuring C-terminal phosphorylation and correlating with neurodegeneration. Reduction of extracellular TDP-43 protects neurons from TDP-43 induced pathology and death. SNP210 is a human autoantibody isolated from patient with high affinity of disease-variant of TDP-43. Targeted disease indications include amyotrophic lateral sclerosis (ALS) and certain forms of frontotemporal dementia (FTD).

SNP201

Alpha-synuclein is a major component of Lewy bodies, a pathological hallmark of synucleinopathathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). SNP201 is a high affinity alpha-synuclein antibody, binding preferentially to aggregated forms of alpha-synuclein known to be pathogenic. Superior binding affinity and epitope recognition enable a favorable target engagement to achieve better clinical efficacy.

SNP318

Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) is an enzyme that hydrolyzes oxidized phospholipids typically on low-density lipoprotein (LDL) to yield lysophosphatidylcholine (lysoPC), a potent proinflammatory factor in both CNS and periphery. LysoPC induces vascular inflammation, which leads to damages in blood vessels in the brain including blood-brain barrier (BBB). SNP318 is a CNS-penetrant inhibitor of Lp-PLA2 with the potential to repair BBB, thereby restoring vascular health and improving cognition in dementias such as Alzheimer’s disease (AD).

SNP234

Amyloid plaques are a hallmark of Alzheimer’s disease and certain other neurodegenerative disorders. A major component of these plaques, aggregated beta-amyloid proteins, are widely considered central to pathogenesis. SNP234 is a next-generation anti-amyloid antibody with exceptional potency and selectivity for toxic aggregated species over healthy monomeric forms. By removing pathogenic aggregates and preventing their further deposition, SNP234 holds promise as a disease-modifying therapeutic that may slow the progression of amyloid-related neurodegeneration and cognitive decline.

SNP203

Progranulin (PGRN) is a secreted glycoprotein growth factor encoded by the GRN gene that plays a critical role in regulating lysosomal function, neuronal health and survival, and inflammation. Loss-of-function mutations in GRN cause frontotemporal dementia (GRN-FTD) and are associated with Alzheimer’s disease (AD). Extracellular PGRN levels are regulated by its cell surface receptor, Sortilin 1 (SORT1), through the endocytic degradation pathway. SNP203 is a best-in-class anti-SORT1 antibody that restores extracellular PGRN levels by blocking the PGRN-SORT1 interaction and reducing PGRN endocytic clearance and thus increasing extra-cellular PGRN levels. Compared to competitor molecules, SNP203 demonstrates superior potency, improved pharmacokinetics (PK), lower dosing requirements, and a more patient-friendly delivery method.